Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
US11999800B2 · kind B2 · utility
0Cited by
34References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2021 |
| Grant date | Jun 4, 2024 |
| Priority date | — |
| Expiry date | May 18, 2041 |
Classification
- Technology area (CPC —)General
Abstract
This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.